Hormone Therapy News

Postmenopausal women with a history of hormone therapy use were biologically younger compared with never-using counterparts, regardless of socioeconomic background, according to study results published in JAMA Network Open.

Transgender youths discussed social concerns, facing hostility and being worried about losing access to care when interviewed about legislation prohibiting gender-affirming care, according to findings published in LGBT Health.

Women with breast cancer who underwent hormone-modulating therapy exhibited a reduced risk for Alzheimer’s disease and related dementias, according to results of a retrospective cohort study.

Lack of available health care providers, health insurance exclusions and a lengthy assessment process are among barriers transgender people face when seeking gender-affirming hormone therapy, according to study findings.

BOSTON — People with primary ovarian insufficiency have higher risk for breast cancer and borderline increased risk for ovarian cancer compared with the general population, and risks for some cancers extend to their relatives, data show.

BOSTON — Menopause is a neurologic transition involving metabolic and immune systems of the brain, and timely estrogen therapy could reduce the risk for developing dementias and other neurogenerative diseases, according to a speaker.

BOSTON — In a phase 2b trial, a hormonal contraceptive gel for use by men worked faster than expected, suppressing sperm count to effective levels by week 8 of use, making it an “attractive” product, according to a speaker at ENDO 2024.

Results of Women’s Health Initiative trials highlight the importance of personalized health care in combination with shared decision-making for postmenopausal women, according to a review published in JAMA.

BOSTON — Most nonbinary people who initiated low-dose transdermal testosterone for gender affirmation continued taking doses that were lower than current guideline recommendations at 1 year, researchers reported at ENDO 2024.

CHICAGO — Cancer risk among women varied based on the type of menopausal hormone therapy they used, according to randomized study results scheduled for presentation at ASCO Annual Meeting.